Answers are grounded in this paper and cite their sources.
Highlights therapeutic strategies targeting vascular calcification in dialysis-dependent end-stage kidney disease, suggesting possible reductions in cardiovascular mortality.
AreWe There Yet? Article, see p 728 C hronic kidney disease (CKD) affects >30 million adults in the United States. 1 Patients with CKD, including those receiving long-term dialysis, are at a disproportionately higher risk for cardiovascular disease and its associated morbidity and mortality than the general population, and this increased risk cannot be fully accounted for by traditional cardiovascular risk factors.3][4] The reason could be the excess risk conferred by nontraditional factors in the setting of derangements of metabolism present in CKD.One such risk factor proposed and investigated is a net positive calcium and phosphate balance, thought to result in hydroxyapatite formation and accelerated vascular calcification. 5,6Even in young adults with dialysis-dependent end-stage kidney disease (ESKD), in whom traditional cardiovascular risk factors are not yet apparent, vascular calcification and coronary artery calcification (CAC) are very prevalent and progressive and are associated with increased cardiovascular mortality. 6alcium-containing phosphate binders, which increase oral calcium intake, may accelerate vascular calcification.8][9] In a trial of 200 dialysis-dependent participants randomized to calcium-containing binders versus sevelamer, the median absolute calcium score in the coronary arteries and aorta increased in the calcium-treated but not in the sevelamer-treated participants (coronary arteries, 36.6 versus 0, P = 0.03; aorta, 75.1 versus 0, respectively, P=0.01). 7In addition, compared with calciumcontaining binders, sevelamer was less likely to cause hypercalcemia and low levels of parathyroid hormone level. 7Treatment with a calcimimetic agent, cinacalcet, which is used to treat secondary hyperparathyroidism in CKD but does not increase serum calcium levels, was also shown to reduce vascular calcification progression in patients with ESKD. 10 After these landmark trials, some data were obtained to suggest that the benefit of such interventions that reduce CAC, a surrogate outcome, may translate to an all-cause mortality benefit in patients with ESKD.[13]
No takes yet. Share an insight, caveat, or question.
S. Susan Hedayati (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: